Vnitr Lek 2019, 65(2):81-85 | DOI: 10.36290/vnl.2019.020

IL-1 family cytokines in chronic inflammatory disorders

Ilja Stříž
Pracoviště klinické a transplantační imunologie IKEM, Praha

IL-1 family represent a group of structurally related cytokines with prevailing pro-inflammatory (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β a IL-37γ) or anti-inflammatory (IL-1Ra, IL-36Ra, IL-38, IL-37) effects. They are involved not only in defense mechanisms and physiological modulation of homeostatic processes, but also in the imunopathogenesis of many diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune and auto-inflammatory diseases. Recently, advances in biologic therapy enabled blocking of IL-1α, IL-1β, IL-18, and IL-33 with new monoclonal antibodies, soluble receptors, or recombinant binding proteins.

Keywords: biologic therapy; cytokines; inflammation; interleukin 1

Received: August 30, 2018; Accepted: November 26, 2018; Published: February 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stříž I. IL-1 family cytokines in chronic inflammatory disorders. Vnitr Lek. 2019;65(2):81-85. doi: 10.36290/vnl.2019.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Striz I, Brabcova E, Kolesar L et al. Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond) 2014; 126(9): 593-612. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20130497>. Go to original source... Go to PubMed...
    2. van de Veerdonk FL, Netea MG. New Insights in the Immunobiology of IL-1 Family Members. Frontiers in immunology 2013; 4: 167. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2013.00167>. Go to original source... Go to PubMed...
    3. Thomas C, Bazan JF, Garcia KC. Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 2012; 19(4): 455-457. Dostupné z DOI: <http://dx.doi.org/10.1038/nsmb.2260>. Go to original source... Go to PubMed...
    4. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 2018; 281(1): 8-27. Dostupné z DOI: <http://dx.doi.org/10.1111/imr.12621>. Go to original source... Go to PubMed...
    5. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479-490. Dostupné z DOI: <http://dx.doi.org/10.1016/j.immuni.2005.09.015>. Go to original source... Go to PubMed...
    6. Brabcova E, Kolesar L, Thorburn E et al. Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. Folia Biol (Praha) 2014; 60(4): 180-186. Go to original source... Go to PubMed...
    7. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999; 162(9): 5070-5077. Go to original source...
    8. Fujita K, Ewing CM, Isaacs WB et al. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer 2011; 129(2): 424-432. Dostupné z DOI: <http://dx.doi.org/10.1002/ijc.25705>. Go to original source... Go to PubMed...
    9. Xie Y, Li Y, Cai X et al. Interleukin-37 suppresses ICAM-1 expression in parallel with NF-kappaB down-regulation following TLR2 activation of human coronary artery endothelial cells. Int Immunopharmacol 2016; 38: 26-30. Dostupné z DOI: <http://dx.doi.org/10.1016/j.intimp.2016.05.003>. Go to original source... Go to PubMed...
    10. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 2015; 97(4): 645-652. Dostupné z DOI: <http://dx.doi.org/10.1189/jlb.3RI1014-495R>. Go to original source... Go to PubMed...
    11. Gunther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol 2014; 193(2): 921-930. Dostupné z DOI: <http://dx.doi.org/10.4049/jimmunol.1400538>. Go to original source... Go to PubMed...
    12. Mora J, Schlemmer A, Wittig I et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol 2016. pii: mjw006. Dostupné z DOI: <http://dx.doi.org/10.1093/jmcb/mjw006>. Go to original source... Go to PubMed...
    13. Danis VA, March LM, Nelson DS et al. Interleukin-1 secretion by peripheral blood monocytes and synovial macrophages from patients with rheumatoid arthritis. Journal Rheumatol1987; 14(1): 33-39.
    14. Firestein GS, Boyle DL, Yu C et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37(5): 644-652. Go to original source... Go to PubMed...
    15. Joosten LA, Radstake TR, Lubberts E et al. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(2): 339-347. Dostupné z DOI: <http://dx.doi.org/10.1002/art.10814>. Go to original source... Go to PubMed...
    16. Matsuyama Y, Okazaki H, Hoshino M et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol Int 2012; 32(5): 1397-1401. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296-011-1854-6>. Go to original source... Go to PubMed...
    17. Boutet MA, Bart G, Penhoat M et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol 2016; 184(2): 159-173. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12761>. Go to original source... Go to PubMed...
    18. Xia L, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: Attenuated the production of inflammatory cytokines. Cytokine 2015; 76(2): 553-557. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2015.06.005>. Go to original source... Go to PubMed...
    19. Italiani P, Manca ML, Angelotti F et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther 2018; 20(1): 27. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075-018-1525-z>. Go to original source... Go to PubMed...
    20. Wu GC, Li HM, Wang JB et al. Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients. Lupus 2016; 25(12): 1377-1380. Dostupné z DOI: <http://dx.doi.org/10.1177/0961203316646462>. Go to original source... Go to PubMed...
    21. Liuqing W, Liping X, Hui S et al. Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjogren's syndrome. J Investig Med 2017; 65(3): 717-721. Dostupné z DOI: <http://dx.doi.org/10.1136/jim-2016-000301>. Go to original source... Go to PubMed...
    22. Ciccia F, Accardo-Palumbo A, Alessandro R et al. Interleukin-36alpha axis is modulated in patients with primary Sjogren's syndrome. Clin Exp Immunol 2015; 181(2): 230-238. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12644>. Go to original source... Go to PubMed...
    23. de Jesus AA, Goldbach-Mansky R. Genetically defined autoinflammatory diseases. Oral Dis 2016; 22(7): 591-604. Dostupné z DOI: <http://dx.doi.org/10.1111/odi.12448>. Go to original source... Go to PubMed...
    24. Tauber M, Bal E, Pei XY et al. IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases. J Invest Dermatol 2016; 136(9): 1811-1819. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jid.2016.04.038>. Go to original source... Go to PubMed...
    25. Shimizu M, Nakagishi Y, Inoue N et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol 2015; 160(2): 277-281. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2015.06.005>. Go to original source... Go to PubMed...
    26. Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365(7): 620-628. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1013068>. Go to original source... Go to PubMed...
    27. Abraham C, Cho JH Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066-2078. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0804647>. Go to original source... Go to PubMed...
    28. Casellas F, Papo M, Guarner F et al. Intracolonic release in vivo of interleukin-1 beta in chronic ulcerative colitis. Clin Sci (Lond) 1995; 89(5): 521-526. Go to original source... Go to PubMed...
    29. Ludwiczek O, Vannier E, Borggraefe I et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004; 138(2): 323-329. Go to original source... Go to PubMed...
    30. Ludwiczek O, Kaser A, Novick D et al. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 2005; 16(1): 27-33.
    31. Nunes T, Bernardazzi C, de Souza HS. Interleukin-33 and inflammatory bowel diseases: lessons from human studies. Mediators Inflamm 2014; 2014: 423957. Dostupné z DOI: <http://dx.doi.org/10.1155/2014/423957>. Go to original source... Go to PubMed...
    32. Hodzic Z, Schill EM, Bolock AM et al. IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine 2017; 100(10): 1-10. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2017.06.017>. Go to original source... Go to PubMed...
    33. Nishida A, Hidaka K, Kanda T et al. Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22(2): 303-314. Dostupné z DOI: <http://dx.doi.org/10.1097/MIB.0000000000000654>. Go to original source... Go to PubMed...
    34. Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine 2015; 75(2): 389-402. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2015.04.009>. Go to original source... Go to PubMed...
    35. Striz I. Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations. Clin Sci (Lond) 2017; 131(17): 2241-2256. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20170098>. Go to original source... Go to PubMed...
    36. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11(8): 633-652. <http://dx.doi.org/10.1038/nrd3800>. Go to original source... Go to PubMed...
    37. Van Tassell BW, Abouzaki NA, Oddi Erdle C et al. Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. J Cardiovasc Pharmacol 2016; 67(6): 544-551. Dostupné z DOI: <http://dx.doi.org/10.1097/FJC.0000000000000378>. Go to original source... Go to PubMed...
    38. Shakoory B, Carcillo JA, Chatham WW et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome reanalysis of a prior phase iii trials. Crit Care Med 2016; 44(2): 275-281. Dostupné z DOI: <http://dx.doi.org/10.1097/CCM.0000000000001402>. Go to original source... Go to PubMed...
    39. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 2014; 20(Suppl 1): S43-S58. Dostupné z DOI: <http://dx.doi.org/10.2119/molmed.2014.00232>. Go to original source... Go to PubMed...
    40. Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367(25): 2396-2406. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1205099>. Go to original source... Go to PubMed...
    41. Issafras H, Corbin JA, Goldfine ID et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1beta antibody with differential receptor-modulating properties. J Pharmacol Exp Ther 2014; 348(1): 202-215. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.113.205443>. Go to original source... Go to PubMed...
    42. Ilowite NT, Prather K, Lokhnygina Y et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66(9): 2570-2579. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38699>. Go to original source... Go to PubMed...
    43. Kosloski MP, Goss S, Wang SX et al. Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1alpha and IL-1beta in Healthy Subjects and Patients With Osteoarthritis of the Knee. J Clin Pharmacol 2016; 56(12): 1582-1590. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.764>. Go to original source... Go to PubMed...
    44. Hong DS, Janku F, Naing A et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 2015; 33(3): 621-631. Dostupné z DOI: <http://dx.doi.org/10.1007/s10637-015-0226-6>. Go to original source... Go to PubMed...
    45. Mistry P, Reid J, Pouliquen I et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther2014; 52(10): 867-879. Dostupné z DOI: <http://dx.doi.org/10.5414/CP202087>. Go to original source... Go to PubMed...
    46. Argiriadi MA, Xiang T, Wu C et al. Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18. J Biol Chem 2009; 284(36): 24478-24489. <http://dx.doi.org/10.1074/jbc.M109.023887>. Go to original source... Go to PubMed...
    47. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 2006; 31(2): 109-116. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03191127>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.